References
- Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47(1):186–192
- Foley RN, Parfrey PS. Risk factors for cardiac morbidity and mortality in dialysis patients. Curr Opin Nephrol Hypertens. 1994;3(6):608–614
- Foley RN, Curtis BM, Randell EW, Parfrey PS. Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. Clin J Am Soc Nephrol. 2010;5(5):805–813
- Harnett JD, Kent GM, Barre PE, Taylor R, Parfrey PS. Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol. 1994;4(7):1486–1490
- McMahon LP, Parfrey PS: Cardiovascular aspects of chronic kidney disease. In: Brenner BM, ed. Brenner and Rector’s The Kidney. 8th ed. Philadelphia: Saunders Elsevier; 2008:1697–1727
- Tsai YC, Chiu YW, Tsai JC, et al. Association of fluid overload with cardiovascular morbidity and all-cause mortality in stages 4 and 5 CKD. Clin J Am Soc Nephrol. 2015;10(1):39–46
- Russo D, Battaglia Y. Clinical significance of FGF-23 in patients with CKD. Int J Nephrol. 2011;2011:364890
- Komaba H. CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of FGF23 Klothoaxis in CKD-MBD. Clin Calcium. 2010;20(7):1028–1036
- Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358–367
- Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450–458
- Devereux RB. Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization, and comparison to other methods. Hypertension. 1987;9(2 Pt 2):II19–26
- Laddha M, Sachdeva V, Diggikar PM, Satpathy PK, Kakrani AL. Echocardiographic assessment of cardiac dysfunction in patients of end stage renal disease on hemodialysis. J Assoc Physicians India. 2014;62(1):28–32.
- Charytan D. Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease. Curr Opin Nephrol Hypertens. 2014;23:578–585
- Davenport A. Will incremental hemodialysis preserve residual function and improve patient survival? Semin Dial. 2015;28(1):16–19
- Leunissen KML. Fluid status in hemodialysed patients. Nephrol Dial Transplant. 1995;10:153–155
- Charra B. ‘Dry weight’ in dialysis: the history of a concept. Nephrol Dial Transplant. 1998;13:1882–1885
- Luik AJ, Charra B, Katzarski K, et al. Blood pressure control and hemodynamic changes in patients on long time dialysis treatment. Blood Purif. 1998;16:197–209
- Wizemann V, Schilling M. Dilemma of assessing volume state: The use and limitations of a clinical score. Nephrol Dial Transplant. 1995;10:2114–2117
- Weiner DE, Brunelli SM, Hunt A, et al. Improving clinical outcomes among hemodialysis patients: a proposal for a “volume first” approach from the chief medical officers of us dialysis providers. Am J Kidney Dis. 2014;64(5):685–695
- Imanishi Y, Kobayashi K, Kawata T, Inaba M, Nishizawa Y. Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases. Ther Apher Dial. 2007;111:S32–37
- Lutsey PL, Alonso A, Selvin E, et al. Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: The atherosclerosis risk in communities study. J Am Heart Assoc. 2014;3(3):e000936
- Agarwal I, Ide N, Ix JH, et al. Fibroblast growth factor-23 and cardiac structure and function. J Am Heart Assoc. 2014;3:e000584
- Diniz H, Frazão JM. The role of fibroblast growth factor 23 in chronic kidney disease-mineral and bone disorder. Nefrologia. 2013;33(6):835–844
- Sany D, Elsawy AE, Aziz A, et al. The value of serum FGF-23 as a cardiovascular marker in HD patients. Saudi J Kidney Dis Transpl. 2014;25(1):44–52